ArticleBMC musculoskeletal disorders2026
Effects of parathyroid hormone on bone augmentation in a rat model of orthodontic treatment: potential involvement of the non-PLC/PKC signaling pathway.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study investigates the effects of parathyroid hormone (PTH) on alveolar bone formation in a rat model of orthodontic treatment, with a specific focus on the non-phospholipase C (PLC)-dependent protein kinase C (PKC) activation pathway. Forty female Sprague-Dawley rats were randomly assigned to either an experimental group receiving daily subcutaneous injections of recombinant human PTH or a control group receiving an equivalent volume of saline. After seven days of pretreatment, an orthodontic tooth movement model was established using a fixed nickel-titanium coil spring exerting 50 g of force to induce mesial displacement of the maxillary first molar. In vitro, MC3T3-E1 osteoblastic cells were divided into five groups to evaluate proliferation and apoptosis under various conditions, including treatment with PTH peptide mimics (G1R19) and the PKC inhibitor Go6983. Histological analysis showed that osteoclast numbers on the pressure side peaked at day 14 in both groups but remained significantly lower in the PTH-treated group across all time points. Dual-energy X-ray absorptiometry demonstrated significantly higher alveolar bone density in the PTH group on days 14, 21, and 28. Although tooth movement distance increased progressively in both groups, no significant difference was observed between them. In vitro, G1R19(1-34) significantly enhanced cell proliferation and reduced apoptosis; these effects were reversed by co-treatment with Go6983, suggesting involvement of a non-PLC-dependent PKC signaling pathway. In conclusion, PTH administration enhances alveolar bone formation, increases bone density, and mitigates root resorption during orthodontic treatment, potentially through activation of a non-PLC-dependent PKC signaling pathway. These findings suggest that PTH or its analogs may serve as effective biological adjuncts in clinical orthodontics to accelerate tooth movement, improve bone health, and minimize treatment-associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.